| Date | Form | Description | Docs | XBRL | Pages |
| 09/25/12 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/24/12 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/24/12 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/24/12 | SC 13G | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
10 | |
| 09/24/12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
6 | |
| 09/24/12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
8 | |
| 09/21/12 | 8-K | Current report filing |
|
10 | |
| 09/21/12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 09/21/12 | DEF 14A | Definitive proxy statements |
|
25 | |
| 09/18/12 | 8-K | Current report filing |
|
49 |
Latest News & Events
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Read More...Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Read More...Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Read More...